Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF ? expression
- 1 September 1999
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 189 (1) , 72-78
- https://doi.org/10.1002/(sici)1096-9896(199909)189:1<72::aid-path401>3.0.co;2-0
Abstract
Vascular endothelial growth factor (VEGF), acidic and basic fibroblast growth factors (FGF-1 and -2), and transforming growth factor β (TGFβ) are potent angiogenic cytokines. Malignant mesothelioma of the pleura presents with a high intra-tumoural microvascular density (IMD) which also has prognostic relevance. This study was designed to verify the immunohistochemical expression of the angiogenic cytokines in mesothelioma as well as in non-neoplastic human mesothelial cells and to study the individual as well as the combined expression of these cytokines in mesothelioma in relation to both IMD and prognosis. In addition, four mesothelioma cell lines were studied by ELISA for the secretion of VEGF and FGF-2 in their supernatants and were shown to contain high levels of both of these cytokines. Immunohistochemically, VEGF, FGF-1 and -2, and TGFβ immunoreactivity was present in 81, 67, 92 and 96 per cent of mesotheliomas, and in 20, 50, 40, and 10 per cent of samples of the non-neoplastic mesothelium, respectively. Co-ordinate expression of the cytokines was observed whereby mesotheliomas expressed more than one cytokine. The combined immunohistochemical expression levels for all four cytokines correlated significantly with both IMD ( p=0·01) and prognosis ( p=0·0013). When studied individually, high FGF-2 expression correlated best with more tumour aggressiveness and worse prognosis for mesothelioma ( p=0·0011). There was no significant correlation between prognosis and immunoexpression of VEGF ( p=0·07), FGF-1 ( p=0·3), or TGFβ ( p=0·1), or between IMD and any of the cytokines studied individually. These data support the assertion that selective angiogenic cytokines might contribute to the progressive changes of mesothelioma by tumour angiogenesis. Copyright © 1999 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcomeThe Journal of Pathology, 1998
- Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases.Environmental Health Perspectives, 1997
- Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase intracellular pathwayBiochimie, 1997
- Addressing tumor blood vesselsNature Biotechnology, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Correlation of Intratumoral Microvessel Density and p53 Protein Overexpression in Human Colorectal AdenocarcinomaMicrovascular Research, 1996
- Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinomaThe Journal of Pathology, 1995
- Transforming growth factor-beta 1 (TGF-β1)- and β2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancerClinical and Experimental Immunology, 1994
- Elevated Levels of an Angiogenic Peptide, Basic Fibroblast Growth Factor, in the Urine of Patients With a Wide Spectrum of CancersJNCI Journal of the National Cancer Institute, 1994
- Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin‐6 production as a common featureInternational Journal of Cancer, 1992